Original article

Profile of the use of disease modifying drugs in the Brazilian Registry of Spondyloarthritides


*Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil

1Instituto Insper de Educação e Pesquisa, São Paulo, SP, Brazil

2Discipline of Rheumatology, Universidade de São Paulo (USP), SP, Brazil

3Universidade de Brasília, Brasília (UnB), DF, Brazil

4Hospital Geral de Goiânia, Goiânia, GO, Brazil

5Hospital Estadual de Campinas (UNICAMP), SP, Brazil

6Universidade Federal do Amazonas, Manaus (UFAM), AM, Brazil

7Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Porto Alegre, RS, Brazil

8Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, SP, Brazil

9Hospital Evangélico de Curitiba, Curitiba, PR, Brazil

10Universidade Federal do Rio de Janeiro (UERJ), Rio de Janeiro, RJ, Brazil

11Universidade Federal de Lavras (UFLA), Lavras, MG, Brazil

12Hospital da Base, Brasília, DF, Brazil

13Universidade Federal do Mato Grosso (UFMT), Célio, MS, Brazil

14Universidade Federal de Pernambuco (UFPE), Recife, PE, Brazil

15Faculdade de Medicina Souza Marques, Rio de Janeiro, RJ, Brazil

16Hospital do Servidor Público Estadual, São Paulo, SP, Brazil

17Instituto de Ortopedia e Traumatologia, Universidade de São Paulo (USP), São Paulo, SP, Brazil

18Universidade Federal de Santa Catarina (UFSC), Florianópolis, SC, Brazil

19Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brazil

20Santa Casa de Belo Horizonte, Belo Horizonte, MG, Brazil

* Corresponding author.
E-mail: pdsampaiobarros@uol.com.br (P.D. Sampaio-Barros).

0482-5004/$ - see front matter. © 2014 Elsevier Editora Ltda. All rights reserved.
http://dx.doi.org/10.1016/j.rbre.2014.02.004
Perfil do uso de drogas modificadoras de doença no registro brasileiro de espondiloartrites

PALAVRAS-CHAVE: Espondiloartrites, Tratamento, Drogas modificadoras de doença, Metotrexato, Sulfasalazina

Perfil do uso de drogas modificadoras de doença no registro brasileiro de espondiloartrites

INTRODUÇÃO: Poucos estudos avaliaram o perfil do uso de drogas modificadoras de doença (DMD) em pacientes brasileiros com diagnóstico de espondiloartrite (EpA).

Métodos: Um protocolo comum de investigação foi prospectivamente aplicado em 1505 pacientes classificados como EpA pelos critérios do European Spondyloarthropathies Study Group (ESSG), acompanhados em 29 centros de referência em Reumatologia no Brasil. Variáveis clínicas e demográficas foram obtidas e avaliadas, analisando-se suas correlações com o uso de DMDs metotrexate (MTX) e sulfasalazina (SSZ).

Resultados: Pelo menos uma DMD foi utilizada por 73,6% dos pacientes, sendo MTX por 29,2% e SSZ por 21,7%, enquanto 22,7% utilizaram ambas as drogas. O uso de MTX foi significativamente associado ao acometimento periférico, e a SSZ foi associada ao comprometimento axial, sendo que as duas drogas foram mais utilizadas, isoladas ou combinadas, no comprometimento misto (p < 0,001). O uso de uma DMD esteve significativamente associado à etnia branca (MTX, p = 0,014), lombalgia inflamatória (SSZ, p = 0,002), dor em nádegas (SSZ, p = 0,030), artrite de membros inferiores (MTX, p < 0,001), artrite de membros superiores (MTX, p < 0,001), entesite (p = 0,007), dactilite (MTX, p < 0,001), doença inflamatória intestinal (SSZ, p < 0,001) e acometimento ungueal (MTX, p < 0,001).

Conclusão: O uso de pelo menos uma DMD foi referido por mais de 70% dos pacientes numa grande coorte brasileira de pacientes com EpA, sendo o uso do MTX mais associado ao acometimento periférico e o uso da SSZ mais associado ao acometimento axial.
Spondyloarthritides are a group of chronic inflammatory diseases with similar clinical and genetic characteristics, which allows their analysis within the same group. Ankylosing spondylitis (AS) is a disease with predominantly axial clinical impairment, while psoriatic arthritis (PA), reactive arthritis, arthritis associated with inflammatory bowel disease and undifferentiated SpA often show an important peripheral involvement. Recognizing this extension of the concept itself, SpAs were recently classified into axial and peripheral. The evaluation of Brazilian and Latin American patients with SpA reveals that, besides the characteristic axial involvement, often a significant number of patients with peripheral involvement are detected.

Studies evaluating the treatment of SpA, especially AS and PA, show that the use of disease-modifying drugs (DMD), such as methotrexate, sulfasalazine, and lefunomide, is related more to the involvement of the peripheral versus axial involvement.

This study analyzes the prescription of DMD for a large cohort of Brazilian patients with SpA.

Patients and methods

This is a prospective, observational, multicenter study with 1505 patients from 29 referral centers participating in the Registro Brasileiro de Espondiloartrites (RBE). All patients fulfilled the criteria of the European Group for the Study of Spondyloarthropathies (ESSG). Data were collected from June 2006 to December 2009. The BRS participates in RESPONDIA (Registro Iberoamericano de Espondiloartrítis) group, consisting of nine Latin American countries (Argentina, Brazil, Costa Rica, Chile, Ecuador, Mexico, Peru, Uruguay and Venezuela) and the two countries of the Iberian Peninsula (Spain and Portugal).

The joint investigation protocol included demographic (gender, race, family history, HLA-B27), osteoarticular clinical (inflammatory back pain, buttock pain, neck pain, hip pain, lower extremity arthritis, arthritis of the lower limbs, enthesitis, dactylitis), extra-articular clinical (uveitis, inflammatory bowel disease [IBD], psoriasis, urethritis), and laboratory (erythrocyte sedimentation rate - ESR and C-reactive protein - CRP) variables.

Patients were evaluated for treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, DMD and biological agents. Regarding the use of DMD, methotrexate (MTX), sulfasalazine (SSZ) and lefunomide (LFN) were evaluated.

For the diagnosis of AS, New York criteria were used; for psoriatic arthritis, the patients had to meet the criteria of Moll and Wright. The diagnosis of reactive arthritis was considered if were present: asymmetric oligoarthritis of the lower limbs with enthesopathies and/or inflammatory lumbar pain arousing after enteric or urogenital infection, and spondylitis/arthritis associated with inflammatory bowel disease, if the patient showed inflammatory axial features and/or peripheral joint involvement, associated with confirmed Crohn’s disease or ulcerative colitis.

Statistical analysis. Categorical variables were compared using χ² and Fisher exact test, and continuous variables were compared using ANOVA. A value of p < 0.05 was considered significant, and 0.05> p> 0.10 was considered as statistical trend.

Results

Data analysis revealed that at least one DMD was used by 73.6% of patients; 51.9% reported the use of MTX - 29.2% as monotherapy and 22.7% with SSZ; and 44.4% used SSZ, of whom 21.7% as monotherapy. The use of lefunomide was reported by 0.2% of patients; for this reason, this agent was not included in the statistical analysis.

With respect to joint involvement, MTX was significantly associated with peripheral involvement and SSZ was associated with axial involvement, and the two drugs were used more often, as monotherapy or in combination, in the mixed involvement (p < 0.001) (Table 1).

The demographic variables showed that MTX was associated with Caucasian ethnicity (p = 0.014). Gender, family history and HLA-B27 were not associated with the use of any DMD (Table 2).

With respect to the clinical picture, MTX was significantly associated with cervical involvement (p = 0.042), arthritis of the lower limbs (p < 0.001), arthritis of the upper limbs (p < 0.001), cutaneous psoriasis (p < 0.001), dactylitis (p < 0.001) and nail involvement (p < 0.001). By the other hand, SSZ was associated with inflammatory back pain (p = 0.002), buttock pain (p = 0.030) and inflammatory bowel disease (p < 0.001), while the use of both drugs was associated with entheses (p = 0.007). Coxofemoral pain, anterior uveitis and urethritis showed no association with the use of DMD (Table 3).

Discussion

This study confirms that the use of DMD is very common in Brazilian patients. In this multicenter study, which included patients from the five Brazilian regions (Southeast, South, Midwest, Northeast and North), the use of at least one DMD was reported by nearly three in four patients with SpA, with 51.7% to MTX and 44.4% to SSZ. The use of at least one DMD may be greatly associated with the significant number of patients with peripheral joint and mixed involvement observed in our cases.

Table 1 – Results of using DMD, according to the clinical picture.

<table>
<thead>
<tr>
<th></th>
<th>MTX(%)</th>
<th>SSZ (%)</th>
<th>MTX + SSZ (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixed</td>
<td>51.8</td>
<td>46.2</td>
<td>58.1</td>
<td></td>
</tr>
<tr>
<td>Axial</td>
<td>24.4</td>
<td>43.0</td>
<td>24.3</td>
<td>&lt; 0.001</td>
</tr>
<tr>
<td>Peripheral</td>
<td>19.2</td>
<td>4.9</td>
<td>8.3</td>
<td></td>
</tr>
<tr>
<td>Enthesial</td>
<td>4.6</td>
<td>5.9</td>
<td>9.3</td>
<td></td>
</tr>
</tbody>
</table>

DMD, disease modifying drug, MTX, methotrexate, SSZ, sulfasalazine.
The use of MTX has been studied in AS in the past two decades. Considering in general that its use is indicated for patients with predominantly axial involvement, the clinical response was not favorable; the only two studies that demonstrated a better response to MTX were Latin American: one Brazilian and one Mexican. Also, the use of MTX for short period of time (16 weeks) might not be enough for the desired effect of the medication. On the other hand, MTX has been used for over 50 years in PA patients, with good results, and in the literature, the use of SSZ in the present study was associated with axial involvement, particularly inflammatory low back pain and buttock pain, and with enteroopathic arthritis.

However, although SSZ is significantly more used than MTX in patients with inflammatory bowel disease, it is noteworthy that less than 9% of patients with this type of impairment were using SSZ. The explanation for this use in patients with axial involvement lies in the fact that many rheumatology services in Brazil use empirically at least one DMD, preferably SSZ, in patients with AS, before prescribing biological agents, since we have an impressive number of patients with mixed (axial and peripheral) joint involvement. Regarding the enthesal involvement, quite frequent in our series, is common practice the prescription of both MTX and SSZ, as monotherapy or in combination, for its treatment.

### Conflicts of interest

The authors declare no conflicts of interest.

The electronic form of the Brazilian Registry of Spondyloarthritis is maintained by an unrestricted grant of Wyeth / Pfizer Brazil, who did not interfere in the data management and statistics. Dr. Sampaio-Barros received a research grant from Federico Foundation, Switzerland.

### REFERENCES


